🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Hepatocellular Carcinoma Resectable

FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma NCT07012798Phase 21 site📍 Tianjin Tianjin Medical University Cancer Institute and Hospital · Tests: Durvalumab, Bevacizumab, HAIC of FOLFOX Triple Therapy Sequential Radiotherapy in Unresectable HCC (TALENP003) NCT06561399n/a4 sites📍 Fuzhou📍 Fuzhou📍 Fuzhou Fujian Provincial Hospital · Tests: TACE, Lenvatinib combination with Sintilimab sequential radiotherapy Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC NCT05608200Phase 31 site📍 Guangzhou Second Affiliated Hospital of Guangzhou Medical University · Tests: Lenvatinib, sintilimab plus TACE, Lenvatinib plus TACE TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant Tumors NCT06487663NA1 site📍 Tianjin Tianjin Medical University Cancer Institute and Hospital · Tests: TACE with ICI HAIC Combined with Donafenib and Sintilimab As Perioperative Treatment for Resectable Hepatocellular Carcinoma Patients At High Risk of Recurrence NCT06812039Phase 23 sites📍 Fuzhou📍 Shanghai📍 Tianjin Fudan University · Tests: HAIC combined with sintilimab and donafenib, Sintilimab and Donafenib, Surgery BioPearl™ Microspheres Loaded With Doxorubicin for the Treatment of Unresectable Hepatocellular Carcinoma (HCC) NCT05911633NA10 sites📍 Brussels📍 Leuven📍 Clichy Terumo Europe N.V. · Tests: BioPearl™ Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo NCT07239245Phase 24 sites📍 Beijing📍 Zhengzhou📍 Shenyang Cancer Institute and Hospital, Chinese Academy of Medical S… · Tests: Atezolizumab, Bevacizumab, Transarterial chemoembolization (TACE) Durvalumab and Tremelimumab in Resectable HCC NCT05440864Phase 23 sites📍 Toronto📍 Milan📍 Pamplona University Health Network, Toronto · Tests: Tremelimumab The Real-world Study of AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING) NCT07064681n/a1 site📍 Guangzhou Sun Yat-sen University · Tests: Surgery with and without the aid of Indocyanine Green (ICG) Atezolizumab Plus Bevacizumab Alone or Combined with External Beam Radiotherapy for HCC with Macrovascular Invasion NCT05992220Phase 21 site📍 Seoul Asan Medical Center · Tests: Atezolizumab plus bevacizumab, combined EBRT to vascular invasion, Atezolizumab plus bevacizumab Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC NCT06041477Phase 31 site📍 Guangzhou Sun Yat-sen University · Tests: Oxaliplatin,calcium folinic acid, levofolinic acid, 5-FU, Concurrent Lenvatinib, Concurrent PD-1 antibody, Sequential L… The Treatment of Bioartificial Liver With hiHep Cells After Extensive Hepatectomy NCT05035108EARLY Phase 11 site📍 Hangzhou Sir Run Run Shaw Hospital · Tests: hiHep bioartificial liver therapy mFOLFOX7 Plus Camrelizumab and Apatinib in BCLC Stage A/B Hepatocellular Carcinoma Patients Beyond Milan Criteria NCT06607107Phase 21 site📍 Guangzhou Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Tests: mFOLFOX7 combined with Camrelizumab and apatinib Sintilimab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC NCT05985798Phase 31 site📍 Guangzhou Second Affiliated Hospital of Guangzhou Medical University · Tests: Sin-Bev-TACE, Len-TACE Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma NCT06582017Phase 111 sites📍 Los Angeles📍 Los Angeles📍 Los Angeles Nammi Therapeutics Inc · Tests: QXL138AM Injection every 2 weeks by IV Infusion SIRT for Potentially Resectable HCC NCT05994859NA1 site📍 Guangzhou Second Affiliated Hospital of Guangzhou Medical University · Tests: SIRT A Study of AK112, a PD-1/ VEGF Bispecific Antibody, for Resectable Hepatocellular Carcinoma With High Recurrence Risk NCT06930573Phase 41 site📍 Zhengzhou The First Affiliated Hospital of Zhengzhou University · Tests: AK112 Radiation Therapy Followed by Durvalumab (MEDI4736) and Tremelimumab And Surgery Versus Radiation Therapy Followed by Surgery for Resectable Hepatocellular Carcinoma. NCT07027436Phase 32 sites📍 Hamilton📍 London Hamilton Health Sciences Corporation · Tests: Chemotherapy/Radiation Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model NCT06420440Phase 22 sites📍 Xiangyang📍 Jinan Chen Xiaoping · Tests: Hepatic arterial infusion chemotherapy, Lenvatinib, Tislelizumab, Liver resection, Tislelizumab Adjuvant Stereotactic Body Radiation Therapy After Trans-arterial Chemoembolization in Hepatocellular Carcinoma NCT04996914NA1 site📍 Aachen RWTH Aachen University · Tests: TACE, SBRT A Two-Arm, Multicenter, Non-Randomized Controlled Study on the Efficacy of Yttrium-90 (Selective Internal Radiation Therapy) Therapy and Hepatic Arterial Infusion Chemotherapy (Hepatic Artery Infusion Chemotherapy) for Potentially Resectable Intermediate and Advanced Hepatocellular Carcinoma NCT07070076NA1 site📍 Guangzhou Li Qiang · Tests: Yttrium-90, HAIC Efficacy and Safety of Sintilimab Combined With Lenvatinib and HAIC for Neoadjuvant Therapy of Borderline Resectable HCC NCT06904014Phase 21 site📍 Jinan Lei ZHAO · Tests: HAIC, Sintilimab, Lenvatinib, surgery Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC) NCT05185739Phase 211 sites📍 Birmingham📍 Cambridge📍 Edinburgh University College, London · Tests: Pembrolizumab, Lenvatinib, Pembrolizumab and Lenvatinib Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring MRD Based on ctDNA NCT06157060n/a7 sites📍 Foshan📍 Guangzhou📍 Guangzhou Zhujiang Hospital · Tests: circulating tumor DNA Iparomlimab/Tuvonralimab Plus SBRT and Lenvatinib for Perioperative Treatment of Potentially Resectable Intermediate-Stage HCC NCT07801287Phase 21 site📍 Tianjin Tianjin Medical University Cancer Institute and Hospital · Tests: Iparomlimab/Tuvonralimab plus SBRT and Lenvatinib Atezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular Carcinoma NCT06133062Phase 21 site📍 Taoyuan City Chang Gung Memorial Hospital · Tests: Atezolizumab, Bevacizumab, Proton radiotherapy Apatinib Mesylate and Camrelizumab Combined With TACE as Neoadjuvant Therapy for Hepatocellular Carcinoma NCT07154082Phase 21 site📍 Wuhan Wei Zhang · Tests: TACE (transarterial chemoembolization) combined with targeted/immunotherapy A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence NCT07475026Phase 31 site📍 Tianjin Tianjin Medical University Cancer Institute and Hospital · Tests: Tislelizumab, Lenvatinib Sintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma NCT07324824Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: sintilimab combined with bevacizumab biosimilar Sintilimab Combined SBRT As Neoadjuvant Therapy for Resectable HCC with PVTT NCT06664996Phase 21 site📍 Chengdu West China Hospital · Tests: stereotactic body radiation therapy (SBRT), Sintilimab (approved)
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy